- gsearch

- gsearch

CDC Stacks Public Health Publications

Search Results

x Driver, Conner
  • Comparative Effectiveness of Moderna PfizerBioNTech and Janssen Johnson  Johnson Vaccines in Preventing COVID19 Hospitalizations Among Adults Without Immunocompromising Conditions  United States MarchAugust 2021
    Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
    :
    :
  • Sustained Effectiveness of PfizerBioNTech and Moderna Vaccines Against COVID19 Associated Hospitalizations Among Adults  United States MarchJuly 2021
    Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
    :
    :
  • Effectiveness of a Third Dose of PfizerBioNTech and Moderna Vaccines in Preventing COVID19 Hospitalization Among Immunocompetent and Immunocompromised Adults  United States AugustDecember 2021
    Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
    :
    :
  • Effectiveness of Monovalent mRNA Vaccines Against COVID19Associated Hospitalization Among Immunocompetent Adults During BA1BA2 and BA4BA5 Predominant Periods of SARSCoV2 Omicron Variant in the United States  IVY Network 18 States December 26 2021August 31 2022
    Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022
    :
    :